Loading page...
Loading page...
Innobio 2 is a life sciences venture capital fund managed by Bpifrance Investissement, investing primarily in France with up to 25% of capital in other European countries. It backs early-clinical-stage biotech and healthcare startups at Series A and B rounds, co-investing alongside VCs with up to €14 million per company. Launched in 2019 as successor to Innobio 1, with a target size above €200 million. Investors include Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, the European Investment Fund, and Pasteur Mutualité.
Choose your AI and follow the walkthrough. Your free EUACC account connects the two.
Illustrated walkthrough
https://www.euacc.ai/api/mcpWorks on every Claude plan, including Free (one custom connector). On Team and Enterprise, an Owner adds it.
On a phone, add it at claude.ai in your browser. It then shows up in the Claude app the next time you sign in.
Use EUACC to explore “Innobio 2” (https://www.euacc.ai/investors/innobio-2). Help me assess investor fit and prepare questions using the available fund profiles. Cite the available sources and flag missing or outdated information.